Biomedica | 血管生成素2可預測COVID-19患者的ICU入院率

Biomedica | 血管生成素2可預測COVID-19患者的ICU入院率


本文轉載自原廠電子報: Biomedica | | 電子報原文

Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Smadja DM et al., Angiogenesis, 2020;1-10. Full text.


Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients. Hultstrom M et al., MedRxiv preprint server, 2021. Full text

Summary of the findings please click here

Click here for product information.

Study discount – 30% off!

Did you know?


Angiopoietin-2 can easily be measured in human serum, plasma and urine samples


√ Low sample volume – only 10µl needed

√ Assay range optimized for clinical samples
√ Ready to use standards and 2 controls included

√ Rigorously validated according to international guidelines

√ Highly specific using epitope mapped antibodies

√ Kit developed and manufactured by Biomedica

Related products:
VEGF, PeriostinNeuropilin-1, Big Endothelin, NT-proBNP, FGF23 ELISA kits

Contact us at Biomedica – Angiopoietin-2, VEGF, Neuropilin-1 ELISA kits – Promotion 30% off (valid until June 30, 2021)

Your Biomedica Immunoassays Team


LINE 線上諮詢



error: Content is protected !!